Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease
- 12 September 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (458)
Abstract
Huntington’s disease (HD) is a genetic progressive neurodegenerative disorder, caused by a mutation in the HTT gene, for which there is currently no cure. The identification of sensitive indicators of disease progression and therapeutic outcome could help the development of effective strategies for treating HD. We assessed mutant huntingtin (mHTT) and neurofilament light (NfL) protein concentrations in cerebrospinal fluid (CSF) and blood in parallel with clinical evaluation and magnetic resonance imaging in premanifest and manifest HD mutation carriers. Among HD mutation carriers, NfL concentrations in plasma and CSF correlated with all nonbiofluid measures more closely than did CSF mHTT concentration. Longitudinal analysis over 4 to 8 weeks showed that CSF mHTT, CSF NfL, and plasma NfL concentrations were highly stable within individuals. In our cohort, concentration of CSF mHTT accurately distinguished between controls and HD mutation carriers, whereas NfL concentration, in both CSF and plasma, was able to segregate premanifest from manifest HD. In silico modeling indicated that mHTT and NfL concentrations in biofluids might be among the earliest detectable alterations in HD, and sample size prediction suggested that low participant numbers would be needed to incorporate these measures into clinical trials. These findings provide evidence that biofluid concentrations of mHTT and NfL have potential for early and sensitive detection of alterations in HD and could be integrated into both clinical trials and the clinic.Keywords
Funding Information
- Wellcome Trust (200181/Z/15/Z)
- CHDI Foundation (A-9856)
- Horizon 2020 Framework Programme (666992)
- Medical Research Council (MR/M008592/1)
- Engineering and Physical Sciences Research Council (EP/M020533/1)
- Wellcome/EPSRC Centre for Medical Engineering (WT 203148/Z/16/Z)
This publication has 54 references indexed in Scilit:
- Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational dataThe Lancet Neurology, 2013
- Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational dataThe Lancet Neurology, 2012
- Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline dataThe Lancet Neurology, 2009
- Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's diseaseParkinsonism & Related Disorders, 2009
- Preparing for Preventive Clinical TrialsArchives of Neurology, 2006
- A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance ImagingArchives of Neurology, 2003
- Voxel-Based Morphometry—The MethodsNeuroImage, 2000
- A nonparametric method for automatic correction of intensity nonuniformity in MRI dataIEEE Transactions on Medical Imaging, 1998
- The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons.Journal of Cell Biology, 1975
- Signal Detectability and Medical Decision-MakingScience, 1971